Researchers investigated whether plasma inflammatory markers were linked to a risk of colorectal cancer and whether the use of anti-inflammatory drugs was differentially linked to risk of CRC according to baseline levels of inflammatory markers, according to a study published in Gastroenterology.
After collecting blood samples from more than 32,000 women, results showed plasma levels of the sTNFR-2, not CRP or IL-6, were linked to an increased risk of CRC. Anti-inflammatory drugs seem to reduce the risk of CRC in women with high, not low, baseline levels of sTNFR-2.
Read the study about the roles of inflammatory markers and NSAIDs in CRC.
Read other coverage about colorectal cancer:
- Researchers Revisit Surveillance Colonoscopy Utilization
- Coding for Screening Colonoscopy When There is Rectal Bleeding: Q&A With Paul Cadorette of mdStrategies
- 4 Steps to Increase Screening Colonoscopy Cases
After collecting blood samples from more than 32,000 women, results showed plasma levels of the sTNFR-2, not CRP or IL-6, were linked to an increased risk of CRC. Anti-inflammatory drugs seem to reduce the risk of CRC in women with high, not low, baseline levels of sTNFR-2.
Read the study about the roles of inflammatory markers and NSAIDs in CRC.
Read other coverage about colorectal cancer:
- Researchers Revisit Surveillance Colonoscopy Utilization
- Coding for Screening Colonoscopy When There is Rectal Bleeding: Q&A With Paul Cadorette of mdStrategies
- 4 Steps to Increase Screening Colonoscopy Cases